♥aetna ®	Paetna [®] Nexviazyme [®] (avalglucosidase alfa-ngpt) Medication Precertification Request					Aetna Precertification Notification Phone: 1-866-752-7021 FAX: 1-888-267-3277	
Page 1 of 2 (All fields must be completed and legible for precertification review.)					For Medicare Advantage Part B: Phone: 1-866-503-0857 FAX: 1-844-268-7263		
Please indicate: Start of treatment	nt, start date:	/ /	Continuation of t	herapy, date of last	treatment:	1 1	
Precertification Requested By:			Phone	:	Fax: _		
A. PATIENT INFORMATION							
First Name:		Last Name:	1				
Address:	1		City:		State:	ZIP:	
Home Phone: Work		Phone:		Cell Phone:			
DOB: Allergies:					E-mail:		
Current Weight: Ibs or	kgs	Height:	inches or	cms			
B. INSURANCE INFORMATION							
Member ID #:		Does patient have other coverage?					
Group #:		If yes, provide ID#: Carrier Name:					
Insured:	Insured:						
Medicare: Yes No If yes, provide ID #: Medicaid: Yes No If yes, provide ID #:							
C. PRESCRIBER INFORMATION First Name: Last Name: (Check one):M.DD.ON.PP.A.							
				(Check one).			
Address:		0413-#	City:		State:	ZIP:	
Phone: Fax:		St Lic #:	NPI #:	DEA #:	Dhamai	UPIN:	
Provider E-mail:	Office Contact Name:			Phone:			
Specialty (Check one): Neurologist Cardiologist Other: D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION							
Place of Administration: Self-administered Place Outpatient Infusion Center Center Name: Home Infusion Center Agency Name: Administration code(s) (CPT): Address:		Physician Physician Specialty Name: Address: Phone:	Dispensing Provider/Pharmacy: (Patient selected choice) Physician's Office Retail Pharmacy Specialty Pharmacy Other: Name:				
Request is for: Nexviazyme (avalglucosidase alfa-ngpt) Dose: Directions for Use: F. DIAGNOSIS INFORMATION - Please indicate primary ICD code and specify any other any other where applicable (*). Directions for Use:							
Primary ICD Code: Other ICD Co							
For All Requests (clinical documentation required for all requests): Yes No Is this infusion request in an outpatient hospital setting? Yes No Has the patient experienced an adverse event with the requested product that has not responded to conventional interventions (e.g. acetaminophen, steroids, diphenhydramine, fluids, other pre-medications or slowing of infusion rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or immediately after an infusion?							
 Yes No Does the patient have laboratory confirmed avalglucosidase alfa antibodies? Yes No Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting? 							
Yes No Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver?							
Yes No Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment? Please provide a description of the condition: Cardiopulmonary:							
Respiratory: Renal: Other:							
Yes No Is the patient diagnosed with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency)?							



H. ACKNOWLEDGEMENT

Patient First Name

Paetna

Request Completed By (Signature Required):

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.

Nexviazyme[®] (avalglucosidase alfa-ngpt) **Medication Precertification Request**

Page 1 of 2

Patient Last Name

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification Phone: 1-866-752-7021 FAX: 1-888-267-3277

For Medicare Advantage Part B: Phone: 1-866-503-0857 FAX: 1-844-268-7263

Patient DOB

G. CLINICAL INFORMATION (continued) - Required clinical information must be completed in its entirety for all precertification requests. For Initiation Requests (clinical documentation required for all requests): □ Yes □ No Was the diagnosis confirmed by enzyme assay demonstrating a deficiency of acid alpha-glucosidase (GAA) enzyme activity OR by genetic testing? For Continuation Requests (clinical documentation required for all requests): Yes No Is the patient responding to therapy (e.g., improvement, stabilization, or slowing of disease progression for motor function, walking capacity, respiratory function, or muscle strength)? Date:

Patient Phone

2025 (9-21)